MI-773 reduces the fraction of CSCs and prevents recurrence in ACC xenograft tumors. MI-773 reduces the fraction of CSCs and prevents recurrence in ACC.

Slides:

Advertisements

Similar presentations

Inhibition of CR HCT-116 (A and B) or CR HT-29 cells (B) xenografts in EPA and/or FuOx-treated SCID mice. Inhibition of CR HCT-116 (A and B) or CR HT-29.

Advertisements

Treatment with BLU9931 leads to tumor regression in the FGF19-overexpressing PDX-derived xenograft LIXC012. Treatment with BLU9931 leads to tumor regression.

Effects of AG-221 treatment on survival and cell differentiation in an IDH2R140Q primary human AML xenograft model. Effects of AG-221 treatment on survival.

Cytotoxic therapy induces macrophage recruitment, as well as CSF1 and IL-34 mRNA expression. Cytotoxic therapy induces macrophage recruitment, as well.

In vivo responses of AMLMLL to ATRi.

Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. AT-3ovadim.

The PI3K–Akt pathway is essential for the in vivo maintenance of murine Tregs. The PI3K–Akt pathway is essential for the in vivo maintenance of murine.

DQ661 improves survival in colon cancer model and potentiates activity of gemcitabine in KPC pancreatic cancer syngeneic model. DQ661 improves survival.

Gr-1+ MDSC in tumor-bearing mice produce IL-6.

B7-H4 expression correlates with MHC-I expression and improved prognosis in patients with breast cancer. B7-H4 expression correlates with MHC-I expression.

Treatment with MI-773 causes changes in p53 status.

Effect of MI-773 and/or cisplatin in a preclinical model of ACC

Activity of MAC-321 (i. v. and p. o

Effect of MI-773 dosing on long-term efficacy.

TH-302 has antileukemia activity in an in vivo primary AML xenograft murine model. TH-302 has antileukemia activity in an in vivo primary AML xenograft.

GR cells are dependent upon sustained CDC25C signaling as pharmacologic or genetic inhibition of CDC25C induce synthetic lethality. GR cells are dependent.

Protracted temozolomide (TMZ) treatment leads to acquired TMZ resistance in glioblastoma (GBM) cells in vivo. Protracted temozolomide (TMZ) treatment leads.

In vivo assessment of synergistic activity of MV-CEA and RT in a U87 s

E-cadherin synthetic lethal effects operate in vivo in E-cadherin–defective breast tumors. E-cadherin synthetic lethal effects operate in vivo in E-cadherin–defective.

Antitumor activity of KM100+5 μmol/L MTX treatment in the presence or absence of CD8+ T cells in BALB-neuT mice bearing subcutaneous tumors of TUBO cells.

EHop-016 and INK128 treatment of myxofibrosarcoma xenografts in NSG mice. EHop-016 and INK128 treatment of myxofibrosarcoma xenografts in NSG mice. A,

CD8, galectin-3, galectin-9, and the M1/M2 ratio are associated with a longer survival. CD8, galectin-3, galectin-9, and the M1/M2 ratio are associated.

The effect of IAA on tumor growth in an SK-MEL-28 xenograft model.

Vascular staining in CWR22R xenograft tumors.

Predictive value of the FGFR3 mutation assay increases with multiple consecutive FGFR3-positive urine samples. Predictive value of the FGFR3 mutation assay.

Overexpression of DDB2 reduces invasive abilities in lungs of aggressive breast tumor cells. Overexpression of DDB2 reduces invasive abilities in lungs.

Antitumor activity of temozolomide (30 mg/kg for 5 days), talazoparib (0.25 mg/kg twice daily for 5 days), or in combination against xenograft models sensitive.

PVHA increased anti-PD-L1–mediated growth inhibition in 4T1/HAS3 tumors. PVHA increased anti-PD-L1–mediated growth inhibition in 4T1/HAS3 tumors. A, 4T1/HAS3.

Paclitaxel treatment along with CXCR2 knockdown reduces tumor growth and metastasis. Paclitaxel treatment along with CXCR2 knockdown reduces tumor growth.

Time course of a G2-M arrest in response to 6-TG compared with IR and VP-16, showing that 6-TG induced a delayed G2-M arrest in MMR+ cells. Time course.

MEDI4736 shows antitumor activity in xenograft mouse models of human cancer. MEDI4736 shows antitumor activity in xenograft mouse models of human cancer.

Combined loss of MPG and ATM sensitizes pGBM cells to temozolomide (TMZ) in vivo. Combined loss of MPG and ATM sensitizes pGBM cells to temozolomide (TMZ)

M-CSFR inhibition decreases tumor-associated macrophages in mesothelioma and improves the DC therapy induced CD8+ T-cell phenotype. M-CSFR inhibition decreases.

A protracted ketogenic diet increases radiation response in H292 lung cancer xenografts given conventional fractionated radiation. A protracted ketogenic.

The responses of H292 and A549 lung cancer xenografts to hypofractionated radiation were enhanced by the ketogenic diet. The responses of H292 and A549.

NT157 treatment inhibits LNCaP xenograft growth and delays castration-resistant progression. NT157 treatment inhibits LNCaP xenograft growth and delays.

Activity of a chemically modified miR-21 inhibitor in human bladder cancer xenografts. Activity of a chemically modified miR-21 inhibitor in human bladder.

Determination of MTD for romidepsin and pralatrexate and associated antitumor activity. Determination of MTD for romidepsin and pralatrexate and associated.

HMQ1611 inhibited breast tumor growth in mice.

Mean cell number in small intestinal crypt (a), small intestinal villus (b), and midcolonic crypt (c) of BALB/c (♦) and DBA/2 (▪) mice after two injections.

Apoptotic cell index percentage (a and b) and mitotic cell index percentage (c and d) in small intestinal (a and c) and midcolonic (b and d) crypts of.

Systemic reovirus treatment targets disseminated human myeloma in vivo

A to C, MetMAb shows strong antitumor activity in the KP4 orthotopic model of pancreatic cancer by ultrasound. A to C, MetMAb shows strong antitumor activity.

Mice treated with DC therapy and/or M-CSFR inhibition were protected from tumor rechallenge with combination therapy-treated mice displaying superior recall.

Tumor-resident CD8+ T cells rapidly expand after IL-15/IL-15Rα complex treatment. Tumor-resident CD8+ T cells rapidly expand after IL-15/IL-15Rα complex.

Increased apoptotic levels after combined treatment with vincristine (VCR) and imatinib. Increased apoptotic levels after combined treatment with vincristine.

Increased apoptotic levels after combined treatment with DXR and imatinib. Increased apoptotic levels after combined treatment with DXR and imatinib. A–D.

Mean weight change from original weight of (a) BALB/c (b) DBA/2 mice after one (♦) or two (▴) injections of 10 mg/kg and one (▪) or two (×) injections.

Association of overall survival and PAP-specific (A, B) and PA2024-specific (C, D) CTL activity at week 26 using categorical (tertile) analysis and continuous.

CDV potentiates the antitumor effect of ionizing radiation in mice intracerebrally implanted with human glioblastoma cells. CDV potentiates the antitumor.

Mean percentage change from baseline in total IGF-I and the R1507 serum concentration values following a single i.v. administration of R mg/kg (n.

Mean body weights (grams) of athymic female mice implanted with MDA-MB-231 breast carcinoma xenografts. Mean body weights (grams) of athymic female mice.

Anti-CD40 activates TAMs and recruits inflammatory monocytes.

RhuαVEGF and rhuαVEGF/paclitaxel mediated growth inhibition in an androgen-independent prostate cancer xenograft model. rhuαVEGF and rhuαVEGF/paclitaxel.

MGA271 exhibits potent in vivo antitumor activity toward tumor cell carcinoma xenografts. MGA271 exhibits potent in vivo antitumor activity toward tumor.

TAE-684 effectively inhibits the growth of H3122 in vivo.

Efficacy of KM100 and/or MTX in BALB/c mice bearing subcutaneous TUBO tumors. Efficacy of KM100 and/or MTX in BALB/c mice bearing subcutaneous TUBO tumors.

Effect of MZ treatment on lung colony formation in an experimental metastasis. Effect of MZ treatment on lung colony formation in an experimental metastasis.

PDL192 and inhibit the growth of xenograft tumors.

A, antitumor activity of temozolomide (30 mg/kg for 5 days), talazoparib (0.25 mg/kg twice daily for 5 days), or in combination against “sensitive” Ewing.

Survival RR enhancement according to the specific protocol in treated mice. Survival RR enhancement according to the specific protocol in treated mice.

Ganetespib suppresses tumor growth and extends survival in ALK+ NSCLC xenografts. Ganetespib suppresses tumor growth and extends survival in ALK+ NSCLC.

Effects of ZOL treatment on pulmonary metastases.

Intratumoral injections of small doses of agonist anti-CD137 mAb to directly act on CD137+ TILs render systemic immunotherapeutic effects that are synergistic.

W. chinensis extract attenuates tumor growth of 103E (a subline of CWR22Rv1) engrafted in the prostate of nude mice. W. chinensis extract attenuates tumor.

Mechanism by which flavopiridol induces cell cycle arrest and apoptosis in rhabdoid tumor cells. Mechanism by which flavopiridol induces cell cycle arrest.

GCS-100 selectively kills KRAS-addicted lung tumors.

In vivo effect of KIN-193 on PTEN-deficient tumors.

Curative effect of W+T treatment in vivo.

Depletion of CD8+, CD4+, and Ly6G+ cells in subcutaneous TUBO tumor-bearing BALB/c mice treated with KM100 + MTX. Depletions were conducted by intraperitoneal.

Presentation transcript:

MI-773 reduces the fraction of CSCs and prevents recurrence in ACC xenograft tumors. MI-773 reduces the fraction of CSCs and prevents recurrence in ACC xenograft tumors. A, Timeline showing the experimental design. B, Graph depicting the fraction of CSCs (ALDHhighCD44high) identify by flow cytometry in xenograft tumors treated with 5 mg/kg cisplatin and/or 200 mg/kg MI-773. Different lowercase letters (a and b) indicate significant differences among groups (P < 0.05). C, Graphs depicting the flow cytometry gates for the percentage of CSCs (Q2) in UM-PDX-HACC-5 tumors treated with cisplatin and/or MI-773. DEAB is showing the control of the reaction. D, Timeline showing the neoadjuvant treatment (Tx) design. E, Graph depicting the fraction of CSCs (ALDHhighCD44high) identify by flow cytometry in UM-PDX-HACC-5 tumors treated with MI-773 or vehicle control. F, Macroscopic view of mice harboring recurrent tumors or tumor-free animals at the end of the experiment. G, Kaplan–Meier curve depicting recurrence-free survival in mice treated either with 200 mg/kg MI-773 or vehicle control. Recurrence was defined as the presence of a palpable tumor. Felipe Nör et al. Clin Cancer Res 2017;23:1036-1048 ©2017 by American Association for Cancer Research